Thymmune Therapeutics is developing a machine learning platform for thymic cell engineering to enhance the generation and function of thymic-derived T-cells. This technology aims to improve the efficacy and precision of T-cell therapies for cancer and autoimmune diseases by optimizing immune cell treatments.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The natural aging process and certain diseases can impair thymus function, leading to a decline in T cell production and overall immune dysfunction. Current methods to restore immune function, such as surgically harvested thymus, face scalability challenges.
Solution
Thymmune Therapeutics is developing a machine learning-driven platform for thymic cell engineering to restore normal immune function. The company's platform uses induced pluripotent stem cell (iPSC)-derived thymic cells, enabling scalable, off-the-shelf cell manufacturing. This approach aims to provide a less invasive method for restoring immune function with high quality and at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-related disorders, and autoimmune diseases, as well as to address immune decline associated with aging.
Target Audience
The primary target audience includes patients with immune-mediated diseases, immunodeficiencies, transplant-related disorders, and autoimmune diseases, as well as individuals experiencing age-related immune decline.
Features
- Machine learning-enabled thymic engineering platform for optimized T-cell development.
- iPSC-derived thymic cell manufacturing for scalable production of off-the-shelf cells.
- Development of therapies for immunodeficiencies, transplant-related disorders, and autoimmune diseases.
- Technology designed to address the biology of immune decline for healthier aging.